Abstracts tagged "PRO and rheumatoid arthritis (RA)"

Abstract Number: 1401 • 2018 ACR/ARHP Annual Meeting
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Itsaso Odriozola¹, Claire-Sophie Coste¹, Thomas Barnetche^2,3, Christophe Richez^4,5, Bernard Bannwarth¹ and Thierry Schaeverbeke⁶, ¹Rheumatology, CHU de Bordeaux, Bordeaux, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ³Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁴UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁶Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Pain and fatigue are common symptoms for patients with rheumatoid arthritis (RA).JAK inhibitors (JAKi) already proved similar efficacy on disease activity as bDMARD (anti-TNF,…
Abstract Number: 2363 • 2018 ACR/ARHP Annual Meeting
Examining Workplace Supports in the Context of RA Disease Activity
W. Benjamin Nowell¹, Kelly Gavigan¹, Guillermo Ernest Gonzales², Shilpa Venkatachalam¹, Jeffrey R. Curtis³, Sheiva Ghazanfari⁴, Danielle Cavazzini⁴ and Leticia Ferri⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Silver School of Social Work, New York University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: RA can diminish patients’ (pts) work productivity and increase the risk of long-term disability, economic insecurity and worsening health, but limited research informs these…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 189 • 2017 ACR/ARHP Annual Meeting
Challenges and Opportunities of Implementing a Patient-Reported Measure of Physical Function through an Online Electronic Health Record Patient Portal in Routine Rheumatology Practice
Jing Li¹, Jinoos Yazdany², Laura Trupin², Zara Izadi³, Milena Gianfrancesco¹, Sarah Goglin¹ and Gabriela Schmajuk⁴, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA
Background/Purpose: Despite significant interest in the collection of patient-reported outcomes (PROs) to make care more patient-centered, few studies have evaluated implementation efforts to collect PROs…
Abstract Number: 508 • 2017 ACR/ARHP Annual Meeting
Improved Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Failed Adalimumab or Placebo Treatment and Were Rescued with Baricitinib
Bruno Fautrel¹, Peter C. Taylor², Kaleb Michaud³, Himanshu Patel⁴, Baojin Zhu⁴, Carol L Gaich⁴, Jiaying Guo⁴, Amanda Quebe⁴ and Yoshiya Tanaka⁵, ¹Paris VI Pierre et Marie Curie University, Paris, France, ²Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the Phase 3 RA-BEAM study, baricitinib (BARI) 4 mg once daily showed significant clinical improvements compared with placebo (PBO) and adalimumab (ADA).1 Switching…
Abstract Number: 1395 • 2017 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Rheumatoid Arthritis: Best Domain, Best Interface
Iris Navarro-Millán¹, Anna Cornelius-Schecter¹, Aprajita Jagpal², Bernadette Johnson³, Liana Fraenkel⁴, Monika M. Safford¹ and Jeffrey R. Curtis², ¹Weill Cornell Medical College, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT
Background/Purpose: Quantifiable measures of patients’ symptoms such as patient reported outcomes (PROs) provides the physician with quantifiable information of subjective symptoms experienced by patients with…
Abstract Number: 3025 • 2016 ACR/ARHP Annual Meeting
The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies
Mark C. Genovese¹, R Westhovens², Arthur Kavanaugh³, Luc Meuleners⁴, Annegret Van der Aa⁴, Pille Harrison⁴ and Chantal Tasset⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³University of California San Diego, La Jolla, CA, ⁴Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that showed rapid and sustained improvements of signs and symptoms of active rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].